Case Reports in Oncological Medicine / 2019 / Article / Tab 1 / Case Report
A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review Table 1 A summary of all case reports describing immunotherapy for lung sarcomatoid carcinomas.
Age/sex Pathology PD-L1 TPS (%) Tx line Treatment Response Duration of ICI treatment Ref 1 66/M Pleomorphic ≧95 2nd Nivolumab PD 6 cycles/discontinue [9 ] 2 59/F Pleomorphic 80-90 3rd Nivolumab PR 19 cycles/ongoing [9 ] 3 83/M Pleomorphic 60-70 4th Nivolumab PR 10 cycles/ongoing [9 ] 4 55/M Pleomorphic 90 2nd Nivolumab PR 9 cycles/discontinue [10 ] 5 62/M Pleomorphic 70 2nd Nivolumab PR 12 cycles/ongoing [11 ] 6 67/M Pleomorphic ≧50 7th Nivolumab PR 8 cycles/ongoing [12 ] 7 74/M Pleomorphic ≧50 3rd Nivolumab PR 28 months/ongoing [13 ] 8 75/M Pleomorphic 90 3rd Nivolumab CR 3 cycles/ongoing [14 ] 9 82/M Pleomorphic 75 1st Pembrolizumab PR 3 cycles/discontinue [15 ] 10 51/M Pleomorphic ≧50 1st Pembrolizumab PR 3 cycles/ongoing [16 ] 11 57/M Sarcomatoid 80-90 1st (post operation recurrence) Nivolumab CR 3 months/ongoing [17 ] 12 60/M Sarcomatoid 100 1st (post operation recurrence) Nivolumab PR 8 months/ongoing [17 ] Present 69/F Giant cell 75 1st Pembrolizumab CR 4 cycles/discontinue —